Sinovac Biotech Ltd.
No.39 Shangdi Xi Rd
387 articles with Sinovac Biotech Ltd.
Sinovac Biotech Ltd. announced today its unaudited financial results for the six months ended June 30, 2018.
Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
Senior management of Sinovac Biotech Ltd. and the lawful directors of Sinovac Hong Kong (“Lawful Directors”), Mr. Yin Weidong and Ms. Wang Nan, have been granted interim injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region
U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares
Sinovac Biotech Ltd. today announced that the United States District Court of the District of Massachusetts denied 1Globe Capital LLC's ("1Globe") August 2018 motion for a preliminary injunction seeking to enjoin Sinovac from issuing shares of Company stock to the PIPE investors or any other individuals pending the outcome of the ongoing litigation between the parties in the High Court of Justice in Antigua and Barbuda.
Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures
Sinovac Biotech Ltd. became aware Monday October 8, 2018 that unauthorized changes have been made to the Hong Kong Companies Registry for Sinovac Biotech (Hong Kong) Limited (“Sinovac HK”) and that unauthorized changes have been made to the Industry and Commerce Bureau of Beijing for Sinovac Biotech Co., Ltd.
Sinovac Biotech Ltd. today announced that the U.S. Department of Justice ("DOJ") has closed its investigation, with no charges, into possible violations of the Foreign Corrupt Practices Act related to allegations that certain Sinovac employees made improper payments to Chinese government officials.
The SEC determined that it will not recommend or pursue an enforcement action against Sinovac at this time.
To safeguard the legitimate interests of Sinovac Biotech Ltd. and its shareholders, the Current Board hereby makes the following statements:
On February 6, 2018, Sinovac Biotech Ltd. held its 2017 Annual Meeting of Shareholders in Beijing, China.
Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), today announced that the company has relaunched its website, at www.sinovacbio.com.
Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
Sinovac Biotech Ltd. announced it has been forced to temporarily suspend its flu vaccine production and destroy the flu vaccines it is currently producing.
Sinovac Biotech Ltd. announced that Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. inappropriately and without authorization seized control of the Company's websites, www.sinovac.com and www.sinovac.com.cn.
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company") today announced it has been forced to destroy the bacterial seeds intended for use in the production of its 23-valent pneumococcal polysaccharide vaccine, or PPV, and to suspend all preparations for and ultimately postpone the China Food and Drug Administration (CFDA) inspection of the manufacturing site necessary for 23-valent PPV production approval
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
Sinovac Biotech Ltd. announced that it will delay the filing of its annual report on Form 20-F for the year 2017.
Sinovac Biotech Ltd. announced that on April 26, 2018, it entered into Amendment No. 2 to the Amalgamation Agreement (the "Amendment") to further amend the Amalgamation Agreement.
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co., Ltd. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018.
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
Sinovac Biotech Ltd. today issued the following statement to set the record straight following a series of false statements and damaging actions by Shandong Sinobioway Biomedicine Co., Ltd. intended to mislead and publicly harm the interest of Sinovac and our shareholders.
Leading provider of biopharmaceutical products in China, today responded to public statements made by other parties falsely claiming to control the Company, including a press release falsely purporting to come from Sinovac itself.
Sinovac Biotech Ltd. announced actions taken to enhance the corporate governance and management of Sinovac Biotech Co., Ltd., the main operating subsidiary of Sinovac.
Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement.